{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:04:50Z","timestamp":1778587490585,"version":"3.51.4"},"reference-count":50,"publisher":"American Association for Cancer Research (AACR)","issue":"10","funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01 CA172503"],"award-info":[{"award-number":["R01 CA172503"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01 CA190473"],"award-info":[{"award-number":["R01 CA190473"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["T32 GM125633"],"award-info":[{"award-number":["T32 GM125633"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["F30 CA213737"],"award-info":[{"award-number":["F30 CA213737"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Although inhibitors of the kinases CHK1, ATR, and WEE1 are undergoing clinical testing, it remains unclear how these three classes of agents kill susceptible cells and whether they utilize the same cytotoxic mechanism. Here we observed that CHK1 inhibition induces apoptosis in a subset of acute leukemia cell lines in vitro, including TP53-null acute myeloid leukemia (AML) and BCR\/ABL\u2013positive acute lymphoid leukemia (ALL), and inhibits leukemic colony formation in clinical AML samples ex vivo. In further studies, downregulation or inhibition of CHK1 triggered signaling in sensitive human acute leukemia cell lines that involved CDK2 activation followed by AP1-dependent TNF transactivation, TNF\u03b1 production, and engagement of a TNFR1- and BID-dependent apoptotic pathway. AML lines that were intrinsically resistant to CHK1 inhibition exhibited high CHK1 expression and were sensitized by CHK1 downregulation. Signaling through this same CDK2\u2013AP1\u2013TNF cytotoxic pathway was also initiated by ATR or WEE1 inhibitors in vitro and during CHK1 inhibitor treatment of AML xenografts in vivo. Collectively, these observations not only identify new contributors to the antileukemic cell action of CHK1, ATR, and WEE1 inhibitors, but also delineate a previously undescribed pathway leading from aberrant CDK2 activation to death ligand\u2013induced killing that can potentially be exploited for acute leukemia treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This study demonstrates that replication checkpoint inhibitors can kill AML cells through a pathway involving AP1-mediated TNF gene activation and subsequent TP53-independent, TNF\u03b1-induced apoptosis, which can potentially be exploited clinically.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-20-1504","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T11:56:04Z","timestamp":1610020564000},"page":"2666-2678","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["CDK2-Mediated Upregulation of TNF\u03b1 as a Mechanism of Selective Cytotoxicity in Acute Leukemia"],"prefix":"10.1158","volume":"81","author":[{"given":"Husheng","family":"Ding","sequence":"first","affiliation":[{"name":"1Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota."},{"name":"2Division of Oncology Research, Mayo Clinic, Rochester, Minnesota."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole D.","family":"Vincelette","sequence":"additional","affiliation":[{"name":"1Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cordelia D.","family":"McGehee","sequence":"additional","affiliation":[{"name":"1Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mira A.","family":"Kohorst","sequence":"additional","affiliation":[{"name":"3Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian D.","family":"Koh","sequence":"additional","affiliation":[{"name":"2Division of Oncology Research, Mayo Clinic, Rochester, Minnesota."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annapoorna","family":"Venkatachalam","sequence":"additional","affiliation":[{"name":"1Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X. Wei","family":"Meng","sequence":"additional","affiliation":[{"name":"1Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota."},{"name":"2Division of Oncology Research, Mayo Clinic, Rochester, Minnesota."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula A.","family":"Schneider","sequence":"additional","affiliation":[{"name":"2Division of Oncology Research, Mayo Clinic, Rochester, Minnesota."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen S.","family":"Flatten","sequence":"additional","affiliation":[{"name":"2Division of Oncology Research, Mayo Clinic, Rochester, Minnesota."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin L.","family":"Peterson","sequence":"additional","affiliation":[{"name":"2Division of Oncology Research, Mayo Clinic, Rochester, Minnesota."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9464-7555","authenticated-orcid":false,"given":"Cristina","family":"Correia","sequence":"additional","affiliation":[{"name":"2Division of Oncology Research, Mayo Clinic, Rochester, Minnesota."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun-Hee","family":"Lee","sequence":"additional","affiliation":[{"name":"2Division of Oncology Research, Mayo Clinic, Rochester, Minnesota."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mrinal","family":"Patnaik","sequence":"additional","affiliation":[{"name":"4Division of Hematology, Mayo Clinic, Rochester, Minnesota."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3647-6345","authenticated-orcid":false,"given":"Jonathan A.","family":"Webster","sequence":"additional","affiliation":[{"name":"5Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Ghiaur","sequence":"additional","affiliation":[{"name":"5Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0903-7390","authenticated-orcid":false,"given":"B. Douglas","family":"Smith","sequence":"additional","affiliation":[{"name":"5Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4754-127X","authenticated-orcid":false,"given":"Judith E.","family":"Karp","sequence":"additional","affiliation":[{"name":"5Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith W.","family":"Pratz","sequence":"additional","affiliation":[{"name":"5Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hu","family":"Li","sequence":"additional","affiliation":[{"name":"1Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry M.","family":"Karnitz","sequence":"additional","affiliation":[{"name":"1Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota."},{"name":"2Division of Oncology Research, Mayo Clinic, Rochester, Minnesota."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4900-7145","authenticated-orcid":false,"given":"Scott H.","family":"Kaufmann","sequence":"additional","affiliation":[{"name":"1Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota."},{"name":"2Division of Oncology Research, Mayo Clinic, Rochester, Minnesota."},{"name":"4Division of Hematology, Mayo Clinic, Rochester, Minnesota."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2021,1,7]]},"reference":[{"key":"2022061706370459800_bib1","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1158\/1078-0432.CCR-09-1029","article-title":"New insights into checkpoint kinase 1 in the DNA damage response signaling network","volume":"16","author":"Dai","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2022061706370459800_bib2","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1158\/1078-0432.CCR-15-0479","article-title":"Molecular pathways: targeting ATR in cancer therapy","volume":"21","author":"Karnitz","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2022061706370459800_bib3","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1080\/13543784.2017.1389895","article-title":"Directing the use of DDR kinase inhibitors in cancer treatment","volume":"26","author":"Brandsma","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"2022061706370459800_bib4","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1158\/0008-5472.CAN-18-3631","article-title":"Exploiting DNA replication stress for cancer treatment","volume":"79","author":"Ubhi","year":"2019","journal-title":"Cancer Res"},{"key":"2022061706370459800_bib5","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/sj.neo.7900175","article-title":"Blocking Chk1 expression induces apoptosis and abrogates the G2 checkpoint mechanism","volume":"3","author":"Luo","year":"2001","journal-title":"Neoplasia"},{"key":"2022061706370459800_bib6","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.18632\/oncotarget.6364","article-title":"A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase","volume":"7","author":"Sakurikar","year":"2016","journal-title":"Oncotarget"},{"key":"2022061706370459800_bib7","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1158\/0008-5472.CAN-16-3409","article-title":"CHK1 inhibition in small-cell lung cancer produces single-agent activity in biomarker-defined disease subsets and combination activity with cisplatin or olaparib","volume":"77","author":"Sen","year":"2017","journal-title":"Cancer Res"},{"key":"2022061706370459800_bib8","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1158\/1535-7163.MCT-16-0504","article-title":"Ras-MEK signaling mediates a critical Chk1-dependent DNA damage response in cancer cells","volume":"16","author":"Lee","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"2022061706370459800_bib9","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1158\/1078-0432.CCR-16-2876","article-title":"The checkpoint kinase 1 inhibitor prexasertib induces regression of preclinical models of human neuroblastoma","volume":"23","author":"Lowery","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2022061706370459800_bib10","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1158\/1078-0432.CCR-18-2728","article-title":"Broad spectrum activity of the checkpoint kinase 1 inhibitor Prexasertib as a single agent or chemopotentiator across a range of preclinical pediatric tumor models","volume":"25","author":"Lowery","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2022061706370459800_bib11","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1158\/1535-7163.MCT-13-0025","article-title":"Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy","volume":"12","author":"Guertin","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"2022061706370459800_bib12","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1021\/acschembio.7b00147","article-title":"Dual targeting of WEE1 and PLK1 by AZD1775 elicits single agent cellular anticancer activity","volume":"12","author":"Wright","year":"2017","journal-title":"ACS Chem Biol"},{"key":"2022061706370459800_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26825","article-title":"Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the pediatric preclinical testing program","volume":"65","author":"Kurmasheva","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"2022061706370459800_bib14","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1158\/0008-5472.CAN-18-2480","article-title":"Differential activity of ATR and WEE1 inhibitors in a highly sensitive subpopulation of DLBCL linked to replication stress","volume":"79","author":"Young","year":"2019","journal-title":"Cancer Res"},{"key":"2022061706370459800_bib15","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.1158\/1078-0432.CCR-19-0448","article-title":"The CHK1 inhibitor prexasertib exhibits monotherapy activity in high-grade serous ovarian cancer models and sensitizes to PARP inhibition","volume":"25","author":"Parmar","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2022061706370459800_bib16","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(18)30009-3","article-title":"Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study","volume":"19","author":"Lee","year":"2018","journal-title":"Lancet Oncol"},{"key":"2022061706370459800_bib17","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1006\/excr.2000.4838","article-title":"Induction of apoptosis by cancer chemotherapy","volume":"256","author":"Kaufmann","year":"2000","journal-title":"Exp Cell Res"},{"key":"2022061706370459800_bib18","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrc2615","article-title":"Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics","volume":"9","author":"Cragg","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"2022061706370459800_bib19","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1126\/science.1090072","article-title":"p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa","volume":"302","author":"Villunger","year":"2003","journal-title":"Science"},{"key":"2022061706370459800_bib20","first-page":"2643","article-title":"Fas-dependent and -independent mechanisms of cell death following DNA damage in human colon carcinoma cells","volume":"60","author":"Petak","year":"2000","journal-title":"Cancer Res"},{"key":"2022061706370459800_bib21","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/89050","article-title":"Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL","volume":"7","author":"Altucci","year":"2001","journal-title":"Nat Med"},{"key":"2022061706370459800_bib22","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1182\/blood-2009-05-222976","article-title":"FOXO3A as a key molecule for all-trans retinoic acid-induced granulocytic differentiation and apoptosis in acute promyelocytic leukemia","volume":"115","author":"Sakoe","year":"2010","journal-title":"Blood"},{"key":"2022061706370459800_bib23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nrm2312","article-title":"Apoptosis: controlled demolition at the cellular level","volume":"9","author":"Taylor","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2022061706370459800_bib24","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1038\/emboj.2011.307","article-title":"Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases","volume":"30","author":"Strasser","year":"2011","journal-title":"EMBO J"},{"key":"2022061706370459800_bib25","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.2741\/3066","article-title":"TNF: a master switch for inflammation to cancer","volume":"13","author":"Sethi","year":"2008","journal-title":"Front Biosci"},{"key":"2022061706370459800_bib26","volume-title":"Atlas of human hematopoietic colonies","author":"Eaves","year":"1995"},{"key":"2022061706370459800_bib27","doi-asserted-by":"crossref","first-page":"840","DOI":"10.5966\/sctm.2016-0034","article-title":"Assessment of drug sensitivity in hematopoietic stem and progenitor cells from acute myelogenous leukemia and myelodysplastic syndrome ex vivo","volume":"6","author":"Knorr","year":"2017","journal-title":"Stem Cells Transl Med"},{"key":"2022061706370459800_bib28","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1182\/blood-2015-02-629485","article-title":"Dual mTOR inhibitiors induce bim-dependent apoptosis in acute lymphoblastic leukmeia via inhibition of eIF4E\/eIF4G and activation of NF-kB\/Egr-1","volume":"127","author":"Yun","year":"2016","journal-title":"Blood"},{"key":"2022061706370459800_bib29","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/leu.2016.357","article-title":"Histone deacetylase inhibitors interrupt HSP90*RASGRP1 and HSP90*CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells","volume":"31","author":"Ding","year":"2017","journal-title":"Leukemia"},{"key":"2022061706370459800_bib30","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1200\/JCO.2015.64.5788","article-title":"Phase I study of LY2606368, a checkpoint kinase 1 inhibitor, in patients with advanced cancer","volume":"34","author":"Hong","year":"2016","journal-title":"J Clin Oncol"},{"key":"2022061706370459800_bib31","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1158\/1535-7163.MCT-10-0928","article-title":"Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening","volume":"10","author":"Guzi","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"2022061706370459800_bib32","first-page":"1065","article-title":"S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine","volume":"61","author":"Shi","year":"2001","journal-title":"Cancer Res"},{"key":"2022061706370459800_bib33","doi-asserted-by":"crossref","first-page":"5364","DOI":"10.1158\/1078-0432.CCR-12-0961","article-title":"Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro","volume":"18","author":"Schenk","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2022061706370459800_bib34","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.molmed.2010.10.009","article-title":"Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics","volume":"17","author":"Ma","year":"2011","journal-title":"Trends Mol Med"},{"key":"2022061706370459800_bib35","doi-asserted-by":"crossref","first-page":"17682","DOI":"10.1074\/jbc.M110.189092","article-title":"Noxa\/Bcl-2 interactions contribute to bortezomib resistance in human lymphoid cells","volume":"286","author":"Smith","year":"2011","journal-title":"J Biol Chem"},{"key":"2022061706370459800_bib36","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/cdd.2015.74","article-title":"MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors","volume":"22","author":"Knorr","year":"2015","journal-title":"Cell Death Differ"},{"key":"2022061706370459800_bib37","doi-asserted-by":"crossref","first-page":"eaal5148","DOI":"10.1126\/scitranslmed.aal5148","article-title":"Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers","volume":"9","author":"Sun","year":"2017","journal-title":"Sci Transl Med"},{"key":"2022061706370459800_bib38","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0092-8674(00)81589-5","article-title":"Bid, a Bcl2 interacting protein, mediates cytochrome C release from mitochondria in response to activation of cell surface death receptors","volume":"94","author":"Luo","year":"1998","journal-title":"Cell"},{"key":"2022061706370459800_bib39","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0092-8674(00)81590-1","article-title":"Cleavage of BID by caspase 8 mediates the mitochondrial damage in the fas pathway of apoptosis","volume":"94","author":"Li","year":"1998","journal-title":"Cell"},{"key":"2022061706370459800_bib40","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000289196","article-title":"Transcriptional control of the TNF gene","volume":"11","author":"Falvo","year":"2010","journal-title":"Curr Dir Autoimmun"},{"key":"2022061706370459800_bib41","doi-asserted-by":"crossref","first-page":"216","DOI":"10.18632\/oncotarget.27400","article-title":"A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib","volume":"11","author":"Blosser","year":"2020","journal-title":"Oncotarget"},{"key":"2022061706370459800_bib42","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1182\/blood-2005-07-2966","article-title":"Adaphostin-induced oxidative stress overcomes BCR\/ABL mutation-dependent and -independent imatinib resistance","volume":"107","author":"Chandra","year":"2006","journal-title":"Blood"},{"key":"2022061706370459800_bib43","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrc.2015.17","article-title":"Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies","volume":"16","author":"Delbridge","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"2022061706370459800_bib44","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nrc864","article-title":"Live or let die: the cell's response to p53","volume":"2","author":"Vousden","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"2022061706370459800_bib45","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1126\/science.aas9090","article-title":"NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination","volume":"362","author":"Ruscetti","year":"2018","journal-title":"Science"},{"key":"2022061706370459800_bib46","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.cell.2019.08.004","article-title":"TNF induces pathogenic programmed macrophage necrosis in tuberculosis through a mitochondrial-lysosomal-endoplasmic reticulum circuit","volume":"178","author":"Roca","year":"2019","journal-title":"Cell"},{"key":"2022061706370459800_bib47","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/ncb3596","article-title":"Mitochondrial permeabilization engages NF-kappaB-dependent anti-tumour activity under caspase deficiency","volume":"19","author":"Giampazolias","year":"2017","journal-title":"Nat Cell Biol"},{"key":"2022061706370459800_bib48","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N Engl J Med"},{"key":"2022061706370459800_bib49","doi-asserted-by":"crossref","first-page":"E5401","DOI":"10.1073\/pnas.1407792111","article-title":"Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms","volume":"111","author":"Rampal","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061706370459800_bib50","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ccr.2006.11.024","article-title":"p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK\/MK2 pathway for survival after DNA damage","volume":"11","author":"Reinhardt","year":"2007","journal-title":"Cancer Cell"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/81\/10\/2666\/3082136\/2666.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/81\/10\/2666\/3082136\/2666.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T16:15:24Z","timestamp":1655482524000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/81\/10\/2666\/665569\/CDK2-Mediated-Upregulation-of-TNF-as-a-Mechanism"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,7]]},"references-count":50,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,1,7]]},"published-print":{"date-parts":[[2021,5,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-20-1504","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22427530.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22427530","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6512716.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6512716","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,7]]}}}